$WVE
Wave Life Sciences Ltd.

2015 Q4 Form 10-Q Financial Statement

#000119312515406371 Filed on December 17, 2015

View on sec.gov

Income Statement

Concept 2015 Q4 2015 Q3 2014 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.750M $2.860M $770.0K
YoY Change 253.77% 271.43%
% of Gross Profit
Research & Development $3.470M $2.132M $585.0K
YoY Change 381.94% 264.44%
% of Gross Profit
Depreciation & Amortization $130.0K $280.0K $100.0K
YoY Change 62.5% 180.0%
% of Gross Profit
Operating Expenses $7.214M $4.990M $1.354M
YoY Change 305.28% 268.54%
Operating Profit -$7.214M -$4.990M -$1.354M
YoY Change 268.54%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net -$20.00K $137.0K $25.00K
YoY Change -200.0% 448.0%
Pretax Income -$7.240M -$4.853M -$1.329M
YoY Change 311.36% 265.16%
Income Tax -$140.0K $83.00K $34.00K
% Of Pretax Income
Net Earnings -$7.099M -$4.936M -$1.363M
YoY Change 305.89% 262.14%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$463.4K -$535.8K -$64.98K
COMMON SHARES
Basic Shares Outstanding 21.55M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q4 2015 Q3 2014 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $161.2M $66.00M
YoY Change 16020.0%
Cash & Equivalents $161.2M $66.04M $2.489M
Short-Term Investments
Other Short-Term Assets $100.0K $1.900M
YoY Change -50.0%
Inventory
Prepaid Expenses
Receivables $0.00 $0.00
Other Receivables $0.00 $0.00
Total Short-Term Assets $161.4M $67.99M
YoY Change 10752.99%
LONG-TERM ASSETS
Property, Plant & Equipment $2.789M $1.954M
YoY Change 119.78%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.300M $1.100M
YoY Change 550.0%
Total Long-Term Assets $4.040M $3.009M
YoY Change 178.43%
TOTAL ASSETS
Total Short-Term Assets $161.4M $67.99M
Total Long-Term Assets $4.040M $3.009M
Total Assets $165.4M $71.00M
YoY Change 5530.5%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.811M $2.875M
YoY Change 2148.8%
Accrued Expenses $600.0K $100.0K
YoY Change 50.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $100.0K $100.0K
YoY Change
Total Short-Term Liabilities $3.818M $3.474M
YoY Change 332.88%
LONG-TERM LIABILITIES
Long-Term Debt $100.0K $100.0K
YoY Change
Other Long-Term Liabilities $163.0K $31.00K
YoY Change 462.07%
Total Long-Term Liabilities $241.0K $125.0K
YoY Change 731.03%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.818M $3.474M
Total Long-Term Liabilities $241.0K $125.0K
Total Liabilities $4.059M $3.599M
YoY Change 345.55%
SHAREHOLDERS EQUITY
Retained Earnings -$35.08M -$27.98M
YoY Change 120.94%
Common Stock $185.3M $22.45M
YoY Change 1758.46%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $153.5M -$3.120M
YoY Change
Total Liabilities & Shareholders Equity $165.4M $71.00M
YoY Change 5530.5%

Cashflow Statement

Concept 2015 Q4 2015 Q3 2014 Q3
OPERATING ACTIVITIES
Net Income -$7.099M -$4.936M -$1.363M
YoY Change 305.89% 262.14%
Depreciation, Depletion And Amortization $130.0K $280.0K $100.0K
YoY Change 62.5% 180.0%
Cash From Operating Activities -$6.670M -$2.850M -$1.190M
YoY Change 437.9% 139.5%
INVESTING ACTIVITIES
Capital Expenditures -$970.0K -$510.0K -$40.00K
YoY Change 3133.33% 1175.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $0.00
YoY Change -100.0%
Cash From Investing Activities -$970.0K -$510.0K -$40.00K
YoY Change 9600.0% 1175.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 102.7M 61.21M 0.000
YoY Change
NET CHANGE
Cash From Operating Activities -6.670M -2.850M -1.190M
Cash From Investing Activities -970.0K -510.0K -40.00K
Cash From Financing Activities 102.7M 61.21M 0.000
Net Change In Cash 95.09M 57.85M -1.230M
YoY Change -7707.2% -4803.25%
FREE CASH FLOW
Cash From Operating Activities -$6.670M -$2.850M -$1.190M
Capital Expenditures -$970.0K -$510.0K -$40.00K
Free Cash Flow -$5.700M -$2.340M -$1.150M
YoY Change 371.07% 103.48%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q3 wve Minimum Number Of Shares To Be Held To Receive Right To Purchase New Securities
MinimumNumberOfSharesToBeHeldToReceiveRightToPurchaseNewSecurities
1212477 shares
CY2015Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
21551423 shares
CY2014Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2489000
CY2015Q3 us-gaap Preferred Stock Liquidation Preference Value
PreferredStockLiquidationPreferenceValue
10000
CY2015Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9223405 shares
CY2015Q3 us-gaap Common Stock No Par Value
CommonStockNoParValue
CY2015Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9223405 shares
CY2015Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
125000
CY2015Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
537000
CY2015Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
406000
CY2015Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
131000
CY2015Q3 us-gaap Stockholders Equity
StockholdersEquity
-3120000
CY2015Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3721000
CY2015Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
31000
CY2015Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2368000
CY2015Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
700000
CY2015Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2875000
CY2015Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-27977000
CY2015Q3 us-gaap Liabilities
Liabilities
3599000
CY2015Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
70996000
CY2015Q3 us-gaap Common Stock Value
CommonStockValue
22446000
CY2015Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1767000
CY2015Q3 us-gaap Liabilities Current
LiabilitiesCurrent
3474000
CY2015Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
43000
CY2015Q3 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
62000
CY2015Q3 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
94000
CY2015Q3 us-gaap Assets
Assets
70996000
CY2015Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1954000
CY2015Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1055000
CY2015Q3 us-gaap Assets Current
AssetsCurrent
67987000
CY2015Q3 us-gaap Deferred Offering Costs
DeferredOfferingCosts
1736000
CY2015Q3 us-gaap Deferred Tax Assets Liabilities Net Current
DeferredTaxAssetsLiabilitiesNetCurrent
64000
CY2015Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
147000
CY2015Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
66040000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
439000
CY2014Q4 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
3901348 shares
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4263472 shares
CY2014Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
CY2014Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
3901348 shares
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4263472 shares
CY2014Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
29000
CY2014Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
605000
CY2014Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
177000
CY2014Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
428000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
2027000
CY2014Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
29000
CY2014Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
152000
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
125000
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-15876000
CY2014Q4 us-gaap Liabilities
Liabilities
911000
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2938000
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
9973000
CY2014Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1209000
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
882000
CY2014Q4 us-gaap Preferred Stock Value
PreferredStockValue
7874000
CY2014Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
56000
CY2014Q4 us-gaap Deferred Tax Assets Liabilities Net Noncurrent
DeferredTaxAssetsLiabilitiesNetNoncurrent
182000
CY2014Q4 us-gaap Assets
Assets
2938000
CY2014Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
200000
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1269000
us-gaap Net Income Loss
NetIncomeLoss
-3480000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-12000
CY2014Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
0
CY2014Q4 us-gaap Assets Current
AssetsCurrent
1487000
CY2014Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
72000
CY2014Q4 us-gaap Deferred Tax Assets Liabilities Net Current
DeferredTaxAssetsLiabilitiesNetCurrent
64000
CY2014Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
103000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-5000
us-gaap Operating Income Loss
OperatingIncomeLoss
-3614000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
240000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
228000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-68000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-7000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3616000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1048000
CY2014Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2478000
CY2015Q3 wve Common Stock Voting Rights Percentage
CommonStockVotingRightsPercentage
0.50 pure
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-3194000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.92
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3792841 shares
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
562000
us-gaap Other Income
OtherIncome
134000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-136000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3386000
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
9602000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
94000
us-gaap Straight Line Rent Adjustments
StraightLineRentAdjustments
-4000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
2050000
us-gaap Operating Expenses
OperatingExpenses
3614000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-248000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
5619000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1672000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5585000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-136000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1942000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
57000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
195000
us-gaap Effect Of Exchange Rate On Cash Continuing Operations
EffectOfExchangeRateOnCashContinuingOperations
-127000
us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
94000
wve Proceeds From Government Grant
ProceedsFromGovernmentGrant
34000
wve Reimbursable Capital Expenditure
ReimbursableCapitalExpenditure
249000
wve Proceeds From Government Grant Reimbursements For Property And Equipment
ProceedsFromGovernmentGrantReimbursementsForPropertyAndEquipment
314000
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-5859000
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
dei Trading Symbol
TradingSymbol
WVE
dei Amendment Flag
AmendmentFlag
false
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.36
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0001631574
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Concentration of Credit Risk</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> Cash is a financial instrument that potentially subjects the Company to concentration of credit risk. The Company uses eight financial institutions to maintain its cash, all of which are high quality, accredited financial institutions and, accordingly, such funds are subject to minimal credit risk. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. The Company has no financial instruments with off-balance sheet risk of loss.</p> </div>
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Registrant Name
EntityRegistrantName
WAVE LIFE SCIENCES LTD.
dei Document Period End Date
DocumentPeriodEndDate
2015-09-30
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>Use of Estimates</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to the valuation of its Series A preferred shares on conversion of the related party notes payable, the valuation of the Company&#x2019;s ordinary shares, the assumptions used to determine the fair value share-based awards, the valuation allowance required for the Company&#x2019;s deferred tax assets, and determining uncertain tax positions and the related liabilities. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Actual results could differ from the Company&#x2019;s estimates.</p> </div>
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
8895660 shares
us-gaap Stockholders Equity Note Stock Split
StockholdersEquityNoteStockSplit
The Company's board of directors and shareholders approved a 50-for-1 forward share split of the Company's outstanding ordinary and Series A preferred shares effective November 18, 2014. Additionally, on November 1, 2015, the Company's board of directors and shareholders approved a 4.0415917-for-1 forward share split of the Company's issued and outstanding ordinary shares, Series A preferred shares and Series B preferred shares.
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
112000
us-gaap Payments For Repurchase Of Initial Public Offering
PaymentsForRepurchaseOfInitialPublicOffering
1417000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
887000
us-gaap Other Income
OtherIncome
155000
us-gaap Net Income Loss
NetIncomeLoss
-12101000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-13000
us-gaap Revenues
Revenues
152000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
10000
us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
182000
CY2014Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
34000
CY2014Q3 us-gaap Operating Expenses
OperatingExpenses
1354000
CY2014Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
585000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
11631000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
40000
us-gaap Liabilities Assumed1
LiabilitiesAssumed1
319000
us-gaap Operating Income Loss
OperatingIncomeLoss
-12084000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
155000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
165000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-193000
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
1055000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12114000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-13000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-11919000
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
0
us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
3210000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
182000
us-gaap Share Based Compensation
ShareBasedCompensation
3210000
us-gaap Straight Line Rent Adjustments
StraightLineRentAdjustments
-4000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-152000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
64992000
us-gaap Operating Expenses
OperatingExpenses
12236000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-1939000
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
62643000
us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
268000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
72857000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5589000
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
11631000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-73000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3210000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6647000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2464000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
462000
us-gaap Effect Of Exchange Rate On Cash Continuing Operations
EffectOfExchangeRateOnCashContinuingOperations
-67000
CY2014Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
769000
CY2014Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
91000
CY2014Q3 wve Reimbursable Capital Expenditure
ReimbursableCapitalExpenditure
0
CY2015Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.54
wve Proceeds From Government Grant
ProceedsFromGovernmentGrant
112000
CY2015Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
9223405 shares
wve Reclassification Of Preferred Stock Value
ReclassificationOfPreferredStockValue
-7874000
wve Reimbursable Capital Expenditure
ReimbursableCapitalExpenditure
3000
wve Proceeds From Government Grant Reimbursements For Property And Equipment
ProceedsFromGovernmentGrantReimbursementsForPropertyAndEquipment
3000
wve Reclassifications From Permanent Equity To Temporary Equity
ReclassificationsFromPermanentEquityToTemporaryEquity
7874000
CY2014Q1 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
9602000
CY2014 wve Collaboration Agreement Upfront Payment
CollaborationAgreementUpfrontPayment
152000
CY2014Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.32
CY2014Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
4263472 shares
CY2014Q3 us-gaap Other Income
OtherIncome
26000
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
-1363000
CY2014Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1354000
CY2014Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
25000
CY2014Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
25000
CY2014Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1413000
CY2014Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-50000
CY2014Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1329000
CY2015Q3 us-gaap Other Income
OtherIncome
111000
CY2015Q3 us-gaap Net Income Loss
NetIncomeLoss
-4936000
CY2015Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
25000
CY2015Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4990000
CY2015Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
112000
CY2015Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
137000
CY2015Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4927000
CY2015Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
9000
CY2015Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4853000
CY2015Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
83000
CY2015Q3 us-gaap Operating Expenses
OperatingExpenses
4990000
CY2015Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2132000
CY2015Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
718000
CY2015Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2858000
CY2015Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
284000
CY2015Q3 wve Reimbursable Capital Expenditure
ReimbursableCapitalExpenditure
0

Files In Submission

Name View Source Status
0001193125-15-406371-index-headers.html Edgar Link pending
0001193125-15-406371-index.html Edgar Link pending
0001193125-15-406371.txt Edgar Link pending
0001193125-15-406371-xbrl.zip Edgar Link pending
d25307d10q.htm Edgar Link pending
d25307dex311.htm Edgar Link pending
d25307dex312.htm Edgar Link pending
d25307dex321.htm Edgar Link pending
d25307dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
wve-20150930.xml Edgar Link completed
wve-20150930.xsd Edgar Link pending
wve-20150930_cal.xml Edgar Link unprocessable
wve-20150930_def.xml Edgar Link unprocessable
wve-20150930_lab.xml Edgar Link unprocessable
wve-20150930_pre.xml Edgar Link unprocessable